International Society of Antioxidants in Nutrition and Health

First International Conference on Avian Influenza in humans:
Latest advances on prevention, therapies and protective measures

Paris Anti-Avian Influenza 2006

Institut Pasteur, Paris - France
June 29-30, 2006
First International Conference on
Avian Influenza in Humans

LATEST ADVANCES ON PREVENTION, THERAPIES AND
PROTECTIVE MEASURES

Institut Pasteur, Paris, France,
June 29-30 2006

Abstract Book Index

Session 1: Introduction

General Introduction
Dr Guenael Rodier, WHO Europe, Communicable Disease Surveillance and Response, Copenhagen, Denmark

Abstract

Economic Impact of the Avian Influenza Propagation
Mr Milan Brahmbhatt, Lead Adviser in the East Asia Region of the World Bank, Washington DC, USA

Abstract + Powerpoint Presentation

The need of a global task force for influenza
Pr Albert Osterhaus, National Influenza Centre and Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

Abstract

Session 2: Focus on H5N1

The Widening Host Range and Changing Pathobiology of Eurasian H5N1 Avian Influenza in Domestic and Wild Birds
Dr David Swayne, Southeast Poultry Research Lab, Agricultural Research Service, Athens, Georgia, USA

Abstract

Influenza H5N1: diagnosis and disease
Dr Menno D. de Jong, Department of Virology, Oxford University Clinical Research Unit (OUCRU), Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

Abstract

Risk of H5N1 mutations and mammalian adaptation.
Dr Erich Hoffmann, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, USA

Abstract + Powerpoint Presentation

Importance of the receptor binding surveillance to detect the jumping of the host range of the highly pathogenic bird influenza virus (H5N1) into humans
Yasuo Suzuki, College of life and health sciences, Chubu University, Aichi, Japan

Abstract
Role of Mathematical Modelling in Pandemic Preparedness
Dr Simon Cauchemez, Department of Infectious Diseases Epidemiology, Imperial College, London, United Kingdom.
Abstract + Powerpoint Presentation

Pathogenesis of H5N1 a/vietnam/1203/04 in a mouse infection model
James Long, Battelle medical research & evaluation facility, Columbus, USA
Abstract

Distinct inhibition patterns of influenza a virus between the two most frequent alleles at the porcine MX1 locus
Mélanie Palm, Faculty of Veterinary Medicine, University of Liège, Belgium.
Abstract

Clinical and laboratory comparison of human infections with dengue, influenza or avian influenza a (H5N1) viruses in Indonesia
Herman Kosasih, Naval Medical Research Unit #2 (NAMRU-2) Jakarta, Indonesia
Abstract

Session 3: H5N1 Detection, Treatments and Perspectives

Avian influenza in humans: existing treatments, their limits, and new perspectives
Pr Erik De Clercq, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Abstract + Powerpoint Presentation

Increased sensitivity to Oseltamivir of the neuraminidase of recent Influenza A (H5N1) viruses
Marie Anne Rameix-Welti, Unité de Génétique Moléculaire des Virus Respiratoires, Institut Pasteur, Paris, France
Abstract

Novel antivirals targeting influenza virus-specific membrane rafts
Cornelia Schroeder, Jado Technologies, Dresden, Germany
Abstract

Multivalent lectins as inhibitors of viral fusion and entry in cells: new antiviral mechanism
Pr Leonid Chernomordik, Section on Membrane Biology, Laboratory of Cellular and Molecular Biophysics, National Institute of Child Health and Human Development, Bethesda, USA
Abstract + Powerpoint Presentation

In silico docking on grid infrastructures to accelerate structure-based design against Influenza A Neuraminidases
Dr Nicolas Jacq, Laboratoire de Physique Corpusculaire of Clermont-Ferrand, CNRS/IN2P3, University of Clermont Ferrand, Aubière, France.
Abstract + Powerpoint Presentation

Electrochemical influenza surveillance system
Dr Dominic Suciu, CombiMatrix Corporation, Mukilteo, USA.
Abstract
The use of real-time NASBA for the diagnosis of H5N1 Influenza and other respiratory viruses
Dr Guy Vernet, Director of the Emerging Pathogens R&D Department, Biomérieux, Marcy L’Etoile, France.

Abstract

An alternative neutralization assay for H5N1 influenza a virus using retroviral pseudotypes
Nigel Temperton, MRC/UCL Centre for Medical Molecular Virology, University College London, London, United Kingdom

Abstract

Development of a real-time PCR assay for the detection of human influenza a (H5N1) virus and sequence comparison of three avian influenza a (H5N1) detected in Switzerland
Yves Thomas, National Centre of Influenza, University Hospital of Geneva, Geneva, Switzerland

Abstract

THE NA-STAR® influenza neuraminidase inhibitor resistance detection kit: chemiluminescence assay for detection and quantification of influenza neuraminidase activity
Corinne Olesen, Applied Biosystems, Bedford, USA

Abstract

Detection of avian influenza A/H5 viral isolates with highly sensitive, specific and inclusive real-time RT-PCR assays
Olga Petrauskene, Applied Biosystems, Foster City, USA

Abstract

Session 4: How to prevent Human and Avian Influenza?

The international response on avian influenza
Dr Christianne Bruscheck, OIE, Paris, France

Abstract + Powerpoint Presentation

Strategies to prevent avian influenza in humans in a non pandemic frame
Pr Didier Houssin, Interministry Delegate for the Fight against Avian Influenza, French Ministry of Health, Paris, France

Prevention through immunization: latest advances on vaccination
Pr Sylvie Van der Werf, Molecular Genetic of Respiratory Viruses Institut Pasteur, Paris, France

Abstract

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.
Dr Suryaprakash Sambhara, Centers for Disease Control and Prevention, Atlanta, USA

Abstract + Powerpoint Presentation

A new approach for an influenza virus live vaccine by modification of the cleavage site of the haemagglutinin by reverse genetics
Juergen Stech, Institute of Virology, University Hospital Giessen-Marburg, Germany

Abstract
Development of vaccines against pandemic influenza: Safety, immunogenicity and prospects of an inactivated split-virion H5N1 influenza vaccine
Dr Agnes Hoffenbach, Influenza Franchise Program Leader, Sanofi Pasteur, Marcy l'Etoile, France
Abstract

Respiratory protection against avian influenza
Pierre Jean Messier, Triosyn Corporation, USA
Abstract

Antiviral effect of catechins in green tea on influenza virus
Pr Baik-Lin Seong, Yonsei University, Seoul, South Korea
Abstract

Pandemic Influenza: a potential role for statins in treatment and prophylaxis
Pr David Fedson, Former Professor of Medicine, University of Virginia School of Medicine, Sergy Haut, France
Abstract

Subtype-diverse inactivation of influenza A viruses including H5N1 with an extract of *Trifolium* species and pomegranate juice
Girish Kotwal, Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town School of Medicine, Cape Town, South Africa
Abstract

Session 5: Disaster Management Response

Medical and non medical challenges in avian influenza pandemic
Pr Jean Philippe Derenne, Department of Pneumology, La Pitié Salpêtrière Hospital, Paris, France
Abstract

Ethical Challenges in Pandemic Planning
Dr Ross E.G. Upshur, Joint Centre for Bioethics Flu Pandemic Working Group Member, University of Toronto, Toronto, Canada
Abstract + Powerpoint Presentation

POSTER SECTION

Anti-influenza Virus Activity of 3-O-alkyl- (+)-catechin and 3-O-alkyl- (-)-epigallocatechin Derivatives
Jae-Min Song, Department of Biotechnology, College of Engineering, Yonsei University, Seoul, Korea
Abstract

Altered expression of the porcine orthomyxovirus resistance gene (mx1) by naturally-occurring polymorphisms in the promoter region
A. Decreux, Faculty of Veterinary Medicine, University of Liège, Belgium
Abstract

Molecular epidemiology of H5N1 strains in South-Western Nigeria
Mariette F. Ducatez, Institute of Immunology, National Public Health Laboratory, Luxembourg
Abstract
Multisite monitoring of human influenza surveillance development networks in India  
Dr Harpreet Kaur, Indian Council of Medical Research, New Delhi, India  
Abstract

Characteristic avian influenza cases in Indonesia July 2005 - June 2006  
Vivi Setiawaty, National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Indonesia  
Abstract

Are The Influenza Antigen Tests Sensitive To H5N1 ?  
Yilmaz, N., The Ministry of Health, Refik Saydam Hygiene Center, National Influenza Reference Center, Ankara, Turkey  
Abstract

Avian Influenza Outbreak in Turkey  
Yilmaz, N., The Ministry of Health, Refik Saydam Hygiene Center, National Influenza Reference Center, Ankara, Turkey  
Abstract

The study of genetic variety of influenza A viruses of high pathogenic H5N1 subtype that were isolated during the epizootic in period from 2005 to 2006 in Russian Federation  
A.M.Shestopalov, National Scientific Center of Virology and Biotechnology “Vector” of Rospotrebnadzor, Novosibirsk, Russia  
Abstract

The hygienic cleansing aid  
Mr. Michael R. Hennigan, Lamar University, Beaumont, TX USA  
Abstract

A successful treatment of the pandemic influenza of 1918 and possible mechanisms of its efficacy  
D. M. Neustadter, Israel  
Abstract

Influenza antivirals and pandemic stockpiles: Approaches to risk-sharing and financing  
Dr Buddhima Lokuge, The Australian National University, Canberra, Australia  
Abstract

Avian Influenza and WTO Sanitary Phytosanitary Rules: The Economics of Transboundary Disease Control in Developing Countries  
Dr Buddhima Lokuge, The Australian National University, Canberra, Australia  
Abstract

Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?  
Dr Buddhima Lokuge, The Australian National University, Canberra, Australia  
Abstract

Knowledge and concern of avian influenza among secondary school students  
Moataz Abdel-Fattah, Preventive Medicine Departments, Al-Hada Armed Forces hospital, Taif, Saudi Arabia.  
Abstract

The Threat of Avian Flu  
Luc Montagnier  
Abstract
Abstract Book Purchase

I would like to purchase the following abstract book (including shipment fees):

| June 28-29: First International Conference on Avian Influenza in Humans: Latest Advances on Prevention, Therapies and Protective Measures | 250 € HT |

TOTAL Amount: .................................... TTC

Mrs, Ms, Mr First Name: ...........................................
Last Name: ................................................................
Company: ......................................................................
Function: ........................................................................
Address: ...............................................................................
Zip Code: ...........................................
City: ..........................................................................
Country: ..........................................................................
Phone: ........................................ Fax: ..................................
Email: ...........................................................................

Payment:
- by bank transfer to National Bank of Paris (BNP), 59 Avenue d’Italie 75013
  Paris.***
  Bank Code:30004
  Agency: 00895
  Account number:00010008521 Key:26
  IBAN : FR 76 3000 4008 9500 0100 0852 126 CODE SWIFT : BNPA FR PPP GB
  ***Fees at your charge
- by certified cheque made payable to Takayama with this form
- by credit card: AMERICAN EXPRESS – EURO/MASTER/ACESS – VISA
  Name of the cardholder: ..................................................
  Credit Card Number: ......................................... Expiry Date: ...............................................
  Date:
  Signature:

Please return this form by fax or mail to:
Paris Anti-Avian Influenza 2006 - TAKAYAMA
15 rue de la Paix - 75002 Paris - France
Phone 00 33 1 55 04 77 55 – Fax : 00 33 1 55 04 77 57
influenza2006@wanadoo.fr - www.isanhn.com